-
Cell Death Dis: Blocking the hypusination effect of EIF5A inhibits the growth of colorectal cancer cells
Time of Update: 2020-12-31
when the cancer reaches advanced stage, the cancer cells move from place to place, resulting in poor prognosis, and the average survival rate of patients with current treatments is only 25-30 months.
-
Cancer Cell: Lu Min et al. found that frost can "resurrect" p53 mutants
Time of Update: 2020-12-31
Recently, Lu Min and other teams worked together at Cancer Cell to identify arsenic trioxide (ATO), a mature drug for acute primary myeloid leukemia that can act as a cysteine reactive compound to save structural p53 mutations.
-
Lancet oncol: Issue 3 Preoperative short course radiotherapy and chemotherapy can improve the prognostic prognostics of patients with local advanced rectal cancer
Time of Update: 2020-12-31
in summary, for such patients, the preoperative chemotherapy used by the study group reduced the likelihood of disease-related treatment failure compared to complementary chemotherapy, and the experimental therapy may be considered as a new standard therapy for high-risk local advanced rectal cancer.
-
Process: Immuno-checkpoint inhibitor therapy accelerates the progression of atherosclerosis plaques
Time of Update: 2020-12-31
study, which included 2,842 patients and 2,842 controls, initially analyzed the correlation between ICI exposure and atherosclerosis cardiovascular events and layered them according to age, cardiovascular history, and cancer type.
, the high incidence of cardiovascular events in cancer patients treated with ICI may be due to the accelerated progression of atherosclerosis.
-
Clin Cancer Res: Co-use of Samisson reduces clinical benefits for patients with glioma who receive immunotherapy
Time of Update: 2020-12-31
, a paper published in the journal Clinical Cancer Research reported that in patients with glioblastoma (GBM) who received immunosuppressants, the overall survival rate of patients treated with dexamisong at the baseline of cerebral edema decreased significantly.
-
Nat Commun: lncRNA MaTAR25 affects the development of breast cancer by regulating the Tns1 gene
Time of Update: 2020-12-31
knock-out of MaTAR25 can cause Tns1 expression to decrease, leading to the recombination of the cytostic skeleton, as well as a decrease in sticky spots and micro fluff.
-
Br J Cancer: Comprehensive analysis of 21 gene recurrence scores in patients with immersive breast catheter cancer accompanied by in-place catheter cancer
Time of Update: 2020-12-31
21 gene recurrence score analysis in IDC or IDC/DCIS breast cancer patients in this study, the researchers analyzed ER-positive, HER2-negative N0-1 patients using 21 gene recurrence scoring algorithms.
-
Nature: Release! Metastasis map of human cancer cells
Time of Update: 2020-12-31
the disturbance of lipid metabolism in these cells inhibited the development of brain metastasis, proposed a treatment strategy to prevent and treat diseases, and demonstrated the effectiveness of MetMap as a resource to support transfer research.
-
J Clin Oncol: The combined ovarian inhibition of tymoxifen significantly prolongs the disease-free survival of patients with pre menoporal breast cancer
Time of Update: 2020-12-31
In pre-menoporary breast cancer patients who completed chemotherapy, ovarian function inhibition (OFS) was added to his tam therapy for 5 years, extending the patient's disease-free survival (DFS).
-
Patient recruitment: Randomized, double-blind, controlled, multi-center clinical studies of patients treated with carellidocy monoantigen or placebo and chemotherapy for non-small cell lung cancer
Time of Update: 2020-12-31
First, the title and background information registration number CTR20202571 related registration number drug name injection with Karelliju monoantitor once used name: drug type biological products cli
-
Nat Commun: The occurrence of intestinal cancer and the maintenance of tumor stem driven by the metastatic genetic regulatory factor Mll1 mediated the Wnt path
Time of Update: 2020-12-31
Previous studies have shown that the Wnt/β-catenin signal transducting path path can regulate the self-renewal of adult stem cells and promote tumor development.
-
NATURE: Chromatin fragmentation helps tumor resistance
Time of Update: 2020-12-31
Recently, researchers published a paper in the journal Nature that sequenced chemotherapy-resistant cell clone isolates throughout the genome and found that chromosomal fragmentation is the main driver of the amplification of circulating chromosome DNA (ecDNA), a process that relies on the catalytic substases of poly (ADP-RNA) polymerases (PARPs) and DNA-dependent protein kinases (DNA-PKcs).
-
Science Advances: PARP1 inhibitors are expected to be an effective treatment strategy for PDAC
Time of Update: 2020-12-31
same time, the researchers also found that the MYBBP1A protein works on the nucleal DNA of cells to promote the activity of growth genes and interacts closely with proteins called PARP1 proteins.
-
BMC Med: Sad... BMJ sub-journal reveals: obesity causes cancer, men and women are different!
Time of Update: 2020-12-31
study, published today in BMC Medicine, a team led by the University of Bristol and the International Agency for Research on Cancer looked at the effects of different body fat measurements on colorectal cancer risk in men and women.
-
NATIONAL HEALTH: The conditions for including cancer screening in Medicare payments are premature
Time of Update: 2020-12-31
On December 23, the official website of the State Administration of Medical Security issued a reply to recommendation No. 5904 of the Third Session of the 13th National People's Congress, in response to the NPC representative's proposal to carry out universal screening for high-risk malignant tumors nationwide, indicating that the conditions for including cancer screening in the scope of medical insurance payments are not yet ripe.
-
First-line immunotherapy for lung cancer! Roche Tecentriq (Tai Sanqi) Japan approved: single-drug first-line treatment PD-L1 high expression NSCLC!
Time of Update: 2020-12-31
data from phase III IMpower110 study show that Tecentriq has significant survival benefits compared to chemotherapy in patients with high expression PD-L1 in first-line treatment, significantly extending total lifetime (OS) by 7.1 months (mid-OS): 20.2 months vs 13.1 months, HR=0.595,95%CI:0.398-0.890, p=0.0106).
-
New research suggests that radiotherapy for patients with multiple myeloma before receiving CAR-T cell therapy appears to be safe and does not affect the efficacy of CAR-T cells
Time of Update: 2020-12-30
NOVEMBER 11, 2020 /--- In a new study, researchers from the University of Pennsylvania's Abramson Cancer Center found that radiotherapy for patients waiting for multiple myeloma made by CAR-T cells was safe and did not disrupt CAR-T cell therapy, the results of which were presented at the annual meeting of the Virtual American Society of Radiological Oncology on October 27, 2020.
-
First major breakthrough in 40 years! New TCR therapy tebentafusp treatment of vine melanoma (UM) Phase 3 clinical significantly extended survival!
Time of Update: 2020-12-30
recently, the company announced positive results in phase 3 IMCgp100-202 clinical trial (NCT03070392) in the treatment of metastasis grape membrane melanoma (mUM) in the study of TCR therapy tebentafusp (IMCgp100).
-
Scientists have developed a new model of bowel cancer that could reveal how cancer cells are resistant to immunotherapy drugs!
Time of Update: 2020-12-30
Finally, the researchers say cibisatamab is a highly promising immunotherapy drug, but not all bowel cancer patients react; the new model developed by the researchers in this study simulates real tumors and the micro-environment around them, which may help researchers quickly articulate how to effectively respond to antibiotic resistance in the lab.
-
Cell sub-journal interpretation! Reveal how scientists are using tissue stem cells to develop new targeted regenerative medicine therapies!
Time of Update: 2020-12-30
Although scientists have been able to use skin stem cells as a successful treatment for burn patients for more than 40 years, stem cell therapy has only recently begun to regain its "viability" because of the ability of scientists to develop most tissue stem cells and strategies to replace or correct genetic mutations involved in genetic diseases.
